Arcellx (ACLX) Stock Price, News & Analysis

Company Overview

Arcellx, Inc. (NASDAQ:ACLX) is a clinical-stage biotechnology company dedicated to developing next-generation cell therapies for patients with hematologic malignancies and solid tumors. The company’s proprietary Advanced Receptor Constructs (ARC) platform enables precise control over immune cell activity and persistence, leveraging engineered receptor scaffolds to enhance safety and efficacy. By integrating modular co-stimulatory signals and safety switches into its constructs, Arcellx aims to address key challenges in the field of adoptive cell therapy, including off-tumor toxicity and limited durability of response.

Arcellx’s lead pipeline consists of autologous CAR T-cell candidates targeting CD19 for B-cell non-Hodgkin lymphoma and BCMA for multiple myeloma, both in early-stage clinical development. Preclinical programs extend the ARC platform to solid tumor antigens and investigational natural killer (NK) and macrophage cell therapies, with the objective of broadening applicability across cancer indications. The company collaborates with academic institutions and manufacturing partners to optimize cell expansion processes and accelerate clinical translation of its product candidates.

Founded in 2018 by a team of immunologists and biotechnology entrepreneurs, Arcellx is headquartered in Chicago, Illinois, with research and manufacturing operations in the United States and a strategic presence in Europe. The leadership team combines deep expertise in cell therapy development, translational research and regulatory affairs, drawing on experience from leading biopharmaceutical organizations and academic cancer centers. This collective insight guides the company’s clinical strategy and innovative approach to receptor design.

Since its inception, Arcellx has progressed rapidly from platform validation to first-in-human studies, underscoring its commitment to delivering transformative therapies. As it advances its clinical programs, the company is focused on generating robust safety and efficacy data, expanding manufacturing capacity and forging partnerships to bring its ARC-based cell therapies to patients worldwide.

Key Stats

• Today's Range: $66.13 to $67.58
• 50-Day Range: $52.77 to $68.10
• 52-Week Range: $47.86 to $107.37
• Volume: 166,184 shs
• Average Volume: 609,990 shs
• Market Capitalization: $3.71 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $111.23
• Consensus Rating: Buy

Arcellx Stock Analysis - MarketRank™

Arcellx scored higher than 60% of companies evaluated by MarketBeat, and ranked 1378th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Arcellx has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 14 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Arcellx has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Arcellx are expected to decrease in the coming year, from ($1.58) to ($2.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcellx is -22.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcellx is -22.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcellx has a P/B Ratio of 8.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

15.80% of the float of Arcellx has been sold short.

Short Interest Ratio / Days to Cover

Arcellx has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Arcellx has recently decreased by 5.17%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcellx does not currently pay a dividend.

Dividend Growth

Arcellx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.80% of the float of Arcellx has been sold short.

Short Interest Ratio / Days to Cover

Arcellx has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Arcellx has recently decreased by 5.17%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.77

News Sentiment

Arcellx has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Arcellx this week, compared to 6 articles on an average week.

Search Interest

5 people have searched for ACLX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

4 people have added Arcellx to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Arcellx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $371,235.00 in company stock.

Percentage Held by Insiders

Only 8.35% of the stock of Arcellx is held by insiders.

Percentage Held by Institutions

96.03% of the stock of Arcellx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACLX Stock Analysis - Frequently Asked Questions

How have ACLX shares performed this year?

Arcellx's stock was trading at $76.69 at the beginning of 2025. Since then, ACLX shares have decreased by 12.3% and is now trading at $67.2950.

How were Arcellx's earnings last quarter?

Arcellx, Inc. (NASDAQ:ACLX) issued its quarterly earnings results on Thursday, May, 8th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.84) by $0.29. The business had revenue of $8.13 million for the quarter, compared to analysts' expectations of $19.51 million. Arcellx had a negative trailing twelve-month return on equity of 35.27% and a negative net margin of 211.46%.

When did Arcellx IPO?

Arcellx (ACLX) raised $132 million in an IPO on Friday, February 4th 2022. The company issued 8,250,000 shares at a price of $15.00-$17.00 per share.

How do I buy shares of Arcellx?

Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arcellx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcellx investors own include Humana (HUM), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), American Water Works (AWK), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACLX
• CIK: 1786205
• Web: arcellx.com
• Phone: 240-327-0603
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $111.23
• High Stock Price Target: $136.00
• Low Stock Price Target: $93.00
• Potential Upside/Downside: +65.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.07
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$107.35 million
• Net Margins: -211.46%
• Pretax Margin: -208.77%
• Return on Equity: -35.27%
• Return on Assets: -22.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.93
• Quick Ratio: 4.93

Sales & Book Value

• Annual Sales: $107.94 million
• Price / Sales: 34.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.41 per share
• Price / Book: 8.00

Miscellaneous

• Outstanding Shares: 55,110,000
• Free Float: 50,506,000
• Market Cap: $3.71 billion
• Optionable: Optionable
• Beta: 0.28